p53 Monoclonal Antibody (BV21C1) (NHP-AB236)


  • This product is an antibody that was generated by immunizing mouse against recombinant human wild type p53. It is used only in in vitro assays.

Detailed Product Description

  • Introduction: The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.
  • Conjugate: None
  • Antibody Isotype: IgG2bκ
  • Applications: Flow Cytometry; IF; IHC; WB

Technical Specifications

  • Host Species: Mouse
  • Species Reactivity: Bovine; Human; Monkey
  • Immunogen: Recombinant human wild type p53 expressed in E. coli

Product Property

  • Purification: Protein G affinity chromatography
  • Format: Liquid
  • Concentration: 0.2 mg/mL
  • Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
  • Storage: Store at 4⁰C. Avoid freez-thaw cycles.

Target Information

  • Clone: BV21C1
  • Clonality: Monoclonal
  • Alternative Names: Antigen NY-CO-13; Cellular tumor antigen p53; Cys 51 Stop; FLJ92943; HGNC11998; mutant tumor protein 53; OTTMUSP00000006194; p53 tumor suppressor; Phosphoprotein p53; transformation-related protein 53; tumor protein 53; Tumor suppressor p53; tumor supressor p53; Tumour Protein p53
  • Entrez Gene ID: 7157
Downloadable Resources Published Data FAQs Customer Reviews
  • p53 Monoclonal Antibody (BV21C1) (NHP-AB236) Data Sheet: Detailed information.

This paper, "Interaction of p53 and ASPPs regulates rESC conversion to the neural fate concomitant with apoptosis," in fact, follows from "p53-regulated transcription function" and derives from p53 tumor suppressor and the Apoptosis-Stimulating Protein of p53 (ASPP) family. This work outlines how the delicate balance of p53 expression, along with activators and inhibitors like ASPP family members, includes ASPP1, ASPP2, and iASPP. It further goes ahead to commit the rESCs to neural fate with the concomitant induction of apoptosis instead of cell cycle arrest.

With the use of the ND culture system, this study demonstrates a clear expression of ASPP1/ASPP2 and iASPP in rESCs and differentiated cells, using FGF-2 and/or HGF. Of some interest is that p53 expression more corresponds to BAX, a pro-apoptotic gene, rather than to p21, a gene related to cell-cycle arrest. This finding means that the activation of neural differentiation from rESCs is associated with apoptosis through p53 interaction with ASPPs, but not through the cell cycle arrest pathway.

The study further highlights this delicate regulatory network of p53 and ASPPs in primate embryonic stem cells within the confluence of neural differentiation and apoptosis. This study carries implications for our understanding of stem cell biology far beyond the need to know how stem cells work, only to satisfy our curiosity.

Dynamic expression of p53 and p53 targets during ND analyzed with western blotting. 1Fig. 1. Dynamic expression of p53 and p53 targets during ND analyzed with western blotting.

Reference

  1. Shuang Wang., et al." Interaction of p53 and ASPPs regulates rhesus monkey embryonic stem cells conversion to neural fate concomitant with apoptosis." Cell Cycl. 17:9, 1146-1153
  1. Q 1: What are the challenges in targeting p53 with monoclonal antibodies for cancer therapy?

    A: High mutation rate of the p53 gene in cancer cells: Mutations of the p53 gene are likely to result in the loss of antigenicity, whereby this changed protein will not be duly recognized by the monoclonal antibodies targeting the changed p53 protein. Furthermore, protein p53 is a short-lived functionality intracellular protein. This introduces a definite challenge of ensuring that the antibodies reach the target within the cancerous cells and bind to it.

There are currently no customer reviews or questions for p53 Monoclonal Antibody (BV21C1) (NHP-AB236). Click the button below to contact us or submit your feedback about this product.

Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NHP Biologicals from Creative Biolabs are for research, diagnostic, or manufacturing purposes only. They may not be intended for or are not approved for any other use.

USA
Tel:
Fax:
Email:
UK (for antibody and medium reagents only)
Tel:
Email:
Germany
Tel:
Email:

Enter your email here to subscribe.

Submit

Follow us on

Copyright © 2024 Creative Biolabs. All rights reserved.
Cart
  • 0
  • 0
Cart